GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment, despite having its own ADC in development.
This move fuels the industry buzz for the promising anti-tumour modality, with GSK doubling down on the modality.
The gold standard of business intelligence.
GSK's acquisition is valued at £268m.
Author's summary: GSK buys Syndivia's ADC for £268m.
More News
- Poland sees strong demand for LNG import capacity following Russian gas transit halt
- Three resilient UK multinationals global managers are excited about | Trustnet
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- UO’s celebration of Indigenous lives - Daily Emerald
- West Indies ease past Bangladesh in first T20I
- Importing beef is not the solution | GABEL
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow